Stock SEARL THE SEARLE COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials The Searle Company Limited

Equities

SEARL

PK0061701014

Pharmaceuticals

End-of-day quote Pakistan S.E.
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
58.11 PKR -1.92% Intraday chart for The Searle Company Limited +1.73% +12.88%
May. 03 The Searle Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
2023 Euro zone sovereign bond yields approach 8-month low ahead of US data RE

Valuation

Fiscal Period: June 2017 2018 2019 2020 2021 2022
Capitalization 1 78,810 62,712 31,133 42,321 58,239 34,020
Enterprise Value (EV) 1 80,154 64,994 34,798 47,293 75,484 52,785
P/E ratio 33.5 x 23.3 x 13.9 x 16.9 x 15.4 x 14.5 x
Yield 1.92% 1.47% 1.71% 1.25% 0.82% -
Capitalization / Revenue 5.92 x 3.82 x 1.72 x 2.07 x 2.22 x 1.14 x
EV / Revenue 6.02 x 3.96 x 1.93 x 2.31 x 2.88 x 1.76 x
EV / EBITDA 26.4 x 17.7 x 9.86 x 10.4 x 13.1 x 8.64 x
EV / FCF 124 x 126 x -13.7 x -61 x -256 x -25.1 x
FCF Yield 0.81% 0.79% -7.32% -1.64% -0.39% -3.99%
Price to Book 8.41 x 5.7 x 2.38 x 2.73 x 2.28 x 1.19 x
Nbr of stocks (in thousands) 345,191 345,191 345,191 345,191 390,066 390,066
Reference price 2 228.3 181.7 90.19 122.6 149.3 87.22
Announcement Date 10/6/17 11/13/18 10/22/19 10/9/20 10/11/21 10/14/22
1PKR in Million2PKR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2017 2018 2019 2020 2021 2022
Net sales 1 13,310 16,396 18,062 20,475 26,220 29,910
EBITDA 1 3,031 3,678 3,529 4,549 5,779 6,108
EBIT 1 2,859 3,458 3,249 4,233 5,297 5,487
Operating Margin 21.48% 21.09% 17.99% 20.68% 20.2% 18.35%
Earnings before Tax (EBT) 1 2,880 3,254 2,832 3,659 5,035 3,661
Net income 1 2,356 2,687 2,241 2,500 3,679 2,352
Net margin 17.7% 16.39% 12.41% 12.21% 14.03% 7.86%
EPS 2 6.825 7.785 6.493 7.241 9.720 6.029
Free Cash Flow 1 647.5 516 -2,546 -775 -294.9 -2,104
FCF margin 4.86% 3.15% -14.1% -3.79% -1.12% -7.03%
FCF Conversion (EBITDA) 21.36% 14.03% - - - -
FCF Conversion (Net income) 27.48% 19.2% - - - -
Dividend per Share 2 4.379 2.676 1.538 1.538 1.231 -
Announcement Date 10/6/17 11/13/18 10/22/19 10/9/20 10/11/21 10/14/22
1PKR in Million2PKR
Estimates

Balance Sheet Analysis

Fiscal Period: June 2017 2018 2019 2020 2021 2022
Net Debt 1 1,344 2,282 3,665 4,972 17,245 18,765
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.4434 x 0.6205 x 1.039 x 1.093 x 2.984 x 3.072 x
Free Cash Flow 1 647 516 -2,546 -775 -295 -2,104
ROE (net income / shareholders' equity) 26.8% 25.6% 18.1% 17.3% 17.8% 8.51%
ROA (Net income/ Total Assets) 14.3% 14% 10.5% 11.4% 8.92% 6.54%
Assets 1 16,516 19,153 21,263 21,909 41,252 35,958
Book Value Per Share 2 27.20 31.90 37.90 44.90 65.60 73.50
Cash Flow per Share 2 0.4600 0.5900 0.7600 0.9700 0.5700 0.5900
Capex 1 580 530 383 164 880 485
Capex / Sales 4.36% 3.24% 2.12% 0.8% 3.36% 1.62%
Announcement Date 10/6/17 11/13/18 10/22/19 10/9/20 10/11/21 10/14/22
1PKR in Million2PKR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
THE SEARLE COMPANY LIMITED Stock The Searle Company Limited
+12.88% 107M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SEARL Stock
  4. Financials The Searle Company Limited